Curatis Holding AG

Curatis raised net revenue in H1 2026 by 51% to CHF 7.9 million, with product sales of CHF 7.4 million and service sales of CHF 0.6 million. The deficit shrank to CHF 0.4 million after −CHF 1.2 million the previous year, and cash and cash equivalents rose to CHF 3.6 million thanks to a convertible instrument placed in May for CHF 3 million. For 2026 the biotech company confirms the revenue guidance raised in June of around CHF 15 million and aims for a breakeven result. For its key project Corticorelin (C-PTBE-01), a meeting with the FDA to define the Phase‑III study design is planned for Q1 2027. » Más en finanzen.net